company background image
PER logo

Percheron Therapeutics ASX:PER Stock Report

Last Price

AU$0.078

Market Cap

AU$70.3m

7D

-2.5%

1Y

41.8%

Updated

22 Jul, 2024

Data

Company Financials +

Percheron Therapeutics Limited

ASX:PER Stock Report

Market Cap: AU$70.3m

PER Stock Overview

Engages in the research and development of novel antisense pharmaceuticals in Australia.

PER fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Percheron Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Percheron Therapeutics
Historical stock prices
Current Share PriceAU$0.078
52 Week HighAU$0.11
52 Week LowAU$0.05
Beta0.94
11 Month Change-10.34%
3 Month Change5.41%
1 Year Change41.82%
33 Year Change-58.95%
5 Year Change56.00%
Change since IPO-96.75%

Recent News & Updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Jun 08
We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Feb 14
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Aug 26
We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26
Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Shareholder Returns

PERAU PharmaceuticalsAU Market
7D-2.5%1.3%0.04%
1Y41.8%59.4%9.1%

Return vs Industry: PER underperformed the Australian Pharmaceuticals industry which returned 59.4% over the past year.

Return vs Market: PER exceeded the Australian Market which returned 9.1% over the past year.

Price Volatility

Is PER's price volatile compared to industry and market?
PER volatility
PER Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement8.3%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market3.2%

Stable Share Price: PER has not had significant price volatility in the past 3 months.

Volatility Over Time: PER's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aJames Garnerwww.PercheronTx.com

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company’s product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.

Percheron Therapeutics Limited Fundamentals Summary

How do Percheron Therapeutics's earnings and revenue compare to its market cap?
PER fundamental statistics
Market capAU$70.32m
Earnings (TTM)-AU$10.85m
Revenue (TTM)AU$2.29m

30.8x

P/S Ratio

-6.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PER income statement (TTM)
RevenueAU$2.29m
Cost of RevenueAU$56.95k
Gross ProfitAU$2.23m
Other ExpensesAU$13.08m
Earnings-AU$10.85m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.012
Gross Margin97.51%
Net Profit Margin-474.51%
Debt/Equity Ratio0%

How did PER perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.